ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,254.18
-0.76%
Dow Jones
38,852.86
-0.55%
Gold vs US Dollar
2,357.915
-0.06%
Brent Oil
84.205
-0.14%
Bitcoin
68,424.56
0.20%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Genprex Inc (GNPX)

  7. Genprex Inc (GNPX) News

Genprex (GNPX)

Genprex Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GNPX
DateTimeSourceHeadlineSymbolCompany
20/05/202421:35Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GNPXGenprex Inc
15/05/202421:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GNPXGenprex Inc
14/05/202413:31PR Newswire (US)Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
13/05/202413:31PR Newswire (US)Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of DirectorsNASDAQ:GNPXGenprex Inc
09/05/202413:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
08/05/202423:08PR Newswire (US)Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerNASDAQ:GNPXGenprex Inc
01/05/202413:31PR Newswire (US)Genprex to Present and Participate at Upcoming May Investor and Industry ConferencesNASDAQ:GNPXGenprex Inc
09/04/202413:31PR Newswire (US)Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingNASDAQ:GNPXGenprex Inc
03/04/202413:31PR Newswire (US)Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
02/04/202413:31PR Newswire (US)Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery SystemNASDAQ:GNPXGenprex Inc
22/03/202420:10PR Newswire (US)Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
19/03/202417:24PR Newswire (US)Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
19/03/202412:36PR Newswire (US)Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
12/03/202413:01PR Newswire (US)Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat CancersNASDAQ:GNPXGenprex Inc
06/03/202414:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
06/03/202413:30PR Newswire (US)Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingNASDAQ:GNPXGenprex Inc
26/02/202413:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
21/02/202421:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
21/02/202421:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
21/02/202421:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
14/02/202419:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GNPXGenprex Inc
07/02/202413:15PR Newswire (US)Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research CollaboratorsNASDAQ:GNPXGenprex Inc
06/02/202412:30PR Newswire (US)Genprex to Present at Upcoming BIO CEO & Investor ConferenceNASDAQ:GNPXGenprex Inc
05/02/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
05/02/202412:30PR Newswire (US)Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
02/02/202412:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
31/01/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
31/01/202413:42PR Newswire (US)Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024NASDAQ:GNPXGenprex Inc
05/01/202421:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
05/01/202412:00PR Newswire (US)Genprex Provides Business Update and Outlook for 2024NASDAQ:GNPXGenprex Inc
 Showing the most relevant articles for your search:NASDAQ:GNPX

Your Recent History

NASDAQ
TMPOW
Tempo Automation
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved